Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 May 1;29(5):1079-1081.
doi: 10.1093/annonc/mdy116.

When is crossover desirable in cancer drug trials and when is it problematic?

A Haslam  1 , V Prasad  2
Affiliations
Editorial

When is crossover desirable in cancer drug trials and when is it problematic?

A Haslam et al. Ann Oncol. .
No abstract available

PubMed Disclaimer

References

    1. Chan A-W, Altman DG.. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005; 365(9465): 1159–1162. - PubMed
    1. Chen EY, Prasad V.. Crossover is not associated with faster trial accrual. Ann Oncol 2018; 29(3): 776–777. - PubMed
    1. Henshall C, Latimer NR, Sansom L, Ward RL.. Treatment switching in cancer trials: issues and proposals. Int J Technol Assess Health Care 2016; 32(03): 167–174. - PubMed
    1. Prasad V. Double-crossed: why crossover in clinical trials may be distorting medical science. J Natl Compr Canc Netw 2013; 11(5): 625–627. - PubMed
    1. Prasad V, Grady C.. The misguided ethics of crossover trials. Contemp Clinl Trials 2014; 37(2): 167–169. - PMC - PubMed

Publication types

MeSH terms

Substances